DELAYED TREATMENT WITH A T-PA ANALOG AND STREPTOKINASE IN A RABBIT EMBOLIC STROKE MODEL

被引:20
作者
PHILLIPS, DA
FISHER, M
DAVIS, MA
SMITH, TW
PANG, RHL
机构
[1] WORCESTER MEM HOSP, MED CTR, DEPT NEUROL, 119 BELMONT ST, WORCESTER, MA 01605 USA
[2] CREAT BIOMOLECULES INC, HOPKINTON, MA USA
[3] UNIV MASSACHUSETTS, SCH MED, DEPT RADIOL, WORCESTER, MA 01605 USA
[4] UNIV MASSACHUSETTS, SCH MED, DEPT PATHOL, WORCESTER, MA 01605 USA
关键词
Animal models; Plasminogen activator; Rabbits; Streptokinase; Tissue-type;
D O I
10.1161/01.STR.21.4.602
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fibrinolytic therapy may be effective in the treatment of ischemic stroke, and clinical trials are under way. We evaluated two fibrinolytic agents, an analogue of tissue plasminogen activator (Fb-Fb-CF, the catalytic fragment of the tissue plasminogen activator molecule with a prolonged serum half-life, n = 10) and streptokinase (n=7), in a rabbit model of embolic stroke. Both agents were given 3 hours after stroke onset, a time relevant to the clinical setting. Fb-Fb-CF was significantly better (p<0.04) than saline (n=7) in restoring blood Bow to previously occluded intracranial arteries, but streptokinase was ineffective. Neither fibrinolytic agent was associated with a substantial risk for intracerebral hemorrhagic side effects. Our study demonstrates that Fb-Fb-CF can safely and effectively reperfuse rabbit intracranial arteries 3 hours after occlusion, while streptokinase does not. © 1990 American Heart Association, Inc.
引用
收藏
页码:602 / 605
页数:4
相关论文
共 23 条
[1]  
[Anonymous], 1988, LANCET, V2, P349
[2]  
[Anonymous], 1986, LANCET, V1, P397
[3]   BIOLOGICAL DIFFERENCES BETWEEN ISCHEMIA, HYPOGLYCEMIA, AND EPILEPSY [J].
AUER, RN ;
SIESJO, BK .
ANNALS OF NEUROLOGY, 1988, 24 (06) :699-707
[4]   BEYOND CORONARY THROMBOLYSIS [J].
BECKER, RC ;
ALPERT, JS .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (07) :1503-1507
[5]   CORONARY THROMBOLYSIS [J].
CAIRNS, JA ;
COLLINS, R ;
FUSTER, V ;
PASSAMANI, ER .
CHEST, 1989, 95 (02) :S73-S87
[6]   HEMORRHAGIC COMPLICATIONS ASSOCIATED WITH THE USE OF INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR IN TREATMENT OF ACUTE MYOCARDIAL-INFARCTION [J].
CALIFF, RM ;
TOPOL, EJ ;
GEORGE, BS ;
BOSWICK, JM ;
ABBOTTSMITH, C ;
SIGMON, KN ;
CANDELA, R ;
MASEK, R ;
KEREIAKES, D ;
ONEILL, WW ;
STACK, RS ;
STUMP, D .
AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) :353-359
[7]  
CENTENO RS, 1985, AM J NEURORADIOL, V6, P589
[8]  
CLARK W M, 1989, Neurology, V39, P183
[9]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237